Lundbeck
Edit

Lundbeck

http://www.lundbeck.com/
Last activity: 16.09.2026
Active
Categories: BiotechHealthcareNeurologyPharmaceuticalPsychiatry
Lundbeck is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best.

An estimated 700 million people worldwide are living with brain diseases and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain diseases – we call this Progress in Mind.

Despite the challenges, Lundbeck remains steadfast in our commitment to deliver innovation that patients need. We work tirelessly to advance neuroscience, develop new and innovative treatments, and support patient communities – all with the aim of restoring brain health and transforming the lives of the millions of people living with a brain disease. Not only does the burden of brain diseases demand action now, it also demands expertise and courage. We know that to get radically different results, we need to pursue radically different approaches.

Our approximately 5,000 employees in more than 50 countries are engaged in the entire value chain throughout research, development, production, marketing, and sales. Our pipeline consists of several R&D programs and our products are available in more than 100 countries. We have research centers in Denmark and California and our production facilities are located in Denmark, France, and Italy.

For additional information, we encourage you to visit our corporate site www.lundbeck.com.

The privacy statement and applicable disclaimer for this company page can be found here: https://www.lundbeck.com/global/linkedin-privacy-notification-and-disclaimer
Likes
587
Website visits
113.1K /mo.
Mentions
211
Location: Denmark
Employees: 5001-10000
Phone: +48 12 348 68 88
Founded date: 1915

Investors 2

Mentions in press and media 211

DateTitleDescription
16.09.2026Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in Japan for the prevention of migraine attacksApproval granted by Japan's Ministry of Health, Labour and Welfare (MHLW) Eptinezumab is the only intravenous (IV) CGRP-targeted preventive treatment approved for the prevention of migraine attacks in adults and launched in over 30 countrie...
24.08.2026European Commission grants orphan designation for Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart for Cushing's syndrome of endogenous originEuropean Commission grants orphan designation for Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart for Cushing's syndrome of endogenous origin Mon, Aug 24, 2026 09:00 CET Report this content The European Commission has gra...
19.08.2026Strong growth from Vyepti® and focused commercial execution drive total revenue growth of +16% CER (+13% CER underlying) in H1 2026VALBY, Denmark, Aug. 19, 2026 /PRNewswire/ -- Key highlights Lundbeck's total revenue grew by +16% CER[1] (+11% DKK) to DKK 13,588 million in the first six months of 2026, with the U.S. and Europe delivering double-digit growth. The perform...
19.08.2026Strong growth from Vyepti[®] and focused commercial execution drive total revenue growth of +16% CER (+13% CER underlying) in H1 2026Strong growth from Vyepti[®] and focused commercial execution drive total revenue growth of +16% CER (+13% CER underlying) in H1 2026 Wed, Aug 19, 2026 07:00 CET Report this content Key highlights Lundbeck’s total revenue grew by +16% CER[1...
19.08.2026Lundbeckfond Invest A/S launches voluntary exchange offer for A-shares in H. Lundbeck A/SLundbeckfond Invest A/S launches voluntary exchange offer for A-shares in H. Lundbeck A/S Wed, Aug 19, 2026 07:06 CET Report this content H. Lundbeck A/S (“Lundbeck”) hereby informs that Lundbeckfond Invest A/S (“Lundbeckfond Invest”), a fu...
11.08.2026Moberg Pharma strengthens organization ahead of European launchMoberg Pharma strengthens organization ahead of European launch Tue, Aug 11, 2026 08:00 CET Report this content STOCKHOLM, August 11, 2026. Moberg Pharma AB (OMX: MOB) announces changes to its management team and strengthens the organizatio...
28.07.2026«Герофарм» не смог оспорить патент Lundbeck на вортиоксетин«Герофарм» не смог оспорить патент Lundbeck на вортиоксетин Роспатент отказал российской компании «Герофарм» в удовлетворении возражения против действия на территории России евразийского патента датской Lundbeck на вортиоксетин — действующе...
23.07.2026Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsyLundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy Thu, Jul 23, 2026 09:00 CET Report this content The U.S. FDA has granted Fast Track designation to Lu AH69593, an oral ...
20.07.2026Lundbeck announces last patient randomized in DEEp OCEAN, a large Phase III trial in developmental and epileptic encephalopathies (DEEs)DEEp OCEAN is a global trial designed to evaluate the investigational molecule bexicaserin for the treatment of seizures associated with DEEs, a diverse group of childhood-onset epilepsies1 Broadest pivotal trial to date, enrolling patients...
20.07.2026Lundbeck announces last patient randomized in DEEp OCEAN, a large Phase III trial in developmental and epileptic encephalopathies (DEEs)Lundbeck announces last patient randomized in DEEp OCEAN, a large Phase III trial in developmental and epileptic encephalopathies (DEEs) Mon, Jul 20, 2026 09:00 CET Report this content DEEp OCEAN is a global trial designed to evaluate the i...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In